KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $2.5 million.

  • Alnylam Pharmaceuticals' Current Deferred Revenue fell 9642.26% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 9642.26%. This contributed to the annual value of $55.5 million for FY2024, which is 8091.88% down from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Current Deferred Revenue stood at $2.5 million, which was down 9642.26% from $15.1 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $290.8 million during Q4 2023, with a 5-year trough of $2.5 million in Q3 2025.
  • Its 5-year average for Current Deferred Revenue is $99.0 million, with a median of $77.1 million in 2023.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 11470.08% in 2024, then tumbled by 9642.26% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $149.5 million in 2021, then surged by 57.56% to $235.5 million in 2022, then grew by 23.45% to $290.8 million in 2023, then crashed by 80.92% to $55.5 million in 2024, then tumbled by 95.42% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $15.1 million for Q2 2025, and $28.2 million during Q1 2025.